Targeting CO2 Levels in Breathing Training for Asthma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 120
- Locations
- 4
- Primary Endpoint
- pCO2 levels (as an indicator of training manipulation success)
Study Overview
Brief Summary
For the proposed randomized controlled treatment study, the investigators plan to compare the effects of this hypoventilation-based breathing training with a control intervention that will focus on breathing regularity and awareness. The two therapeutic procedures are closely matched on important variables such as duration and the nature of patient-therapist interaction, monitoring asthma related status and the medication intake, use of scientific equipment and monitoring devices to increase adherence, and initial plausibility. Asthma patients who will be evaluated before, during, directly after, and at 2 months and 6 months after training.
Detailed Description
For this randomized controlled treatment study, the investigators plan to compare the effects of hypoventilation-based breathing training with a control intervention that will focus on breathing regularity and awareness. The two therapeutic procedures are closely matched on important variables such as duration and the nature of patient-therapist interaction, monitoring asthma related status and the medication intake, use of scientific equipment and monitoring devices to increase adherence, and initial plausibility. Asthma patients will be evaluated before, during, directly after, and at 1 month and 6 months after training. The primary goal of this training is to determine if a capnometry-assisted breathing training to raise end-tidal CO2 will produce more improvement in asthma control than a control training of breathing awareness. The second goal is to determine if capnometry-assisted breathing training for raising pCO2 will lead to higher pCO2 levels after training than before training on all three measures of pCO2 (the 2-hour monitoring, the standardized training sessions, and the homework assignments). The last objective is to determine if the clinical improvement in asthma outcomes for the raise-pCO2 breathing group will be greater in patients with more improvement in their pCO2.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men or women between 18 and 65 years of age
- •Understand and read english adequately
- •A previously documented history of asthma from intermittent to severe (symptoms plus objective documentation of at least partially reversible airflow obstruction)
- •Willing to undergo a 5-session course of breathing training
- •Current asthma symptoms
Exclusion Criteria
- •Clinically significant heart disease
- •Clinically significant cerebrovascular disease
- •Clinically significant thyroid dysfunction
- •Out-of-control diabetes
- •Use of oral corticosteroids in the last 3 months
- •Active smokers or more than 10 pack years
- •Clinically significant chronic obstructive pulmonary disease
- •Clinically significant emphysema
- •Current alcohol and substance dependence
- •Psychotic disorders and high risk for personality disorders
- •Having received previous breathing training exercises for asthma
- •Not willing to abstain from taking the morning dose of their long-term bronchodilator or leukotriene inhibitors or from using their short-acting beta-2 adrenergic agonists or anticholinergic bronchodilators for 8 hours before the pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up assessments (Medication withdrawal will be discouraged if patients should experience significant symptoms before the assessments. They will be offered to reschedule the appointment without any consequences for their enrollment in the study.)
- •Night shift workers
- •Tuberculosis
- •Pregnant, plan on becoming pregnant, or nursing during the course of the study
Arms & Interventions
Breathing Training
Patients will receive biofeedback assisted breathing training
Intervention: Capnometry Assisted Respiration Training (Behavioral)
Breathing Awareness
Patients will receive biofeedback assisted breathing awareness training.
Intervention: Breathing Awareness (Behavioral)
Outcomes
Primary Outcomes
pCO2 levels (as an indicator of training manipulation success)
Time Frame: Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions, patients perform self-assessments on a daily basis throughout, pre- and post-treatment 2h monitoring
diurnal PEF variability (as an indicator of asthma pathophysiology and control)
Time Frame: pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up
Asthma Control Test (as a self-report indicator of asthma control)
Time Frame: Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up. Further assessments will be made at the beginning of each of the five weekly training sessions.
Secondary Outcomes
- reported inhaled corticosteroid use (as self-report and behavioral indicators of asthma control)(Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions)
- physical and mental health status, stress, anxiety and depression (as indicators of general well-being)(Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions)
- respiration rate from capnometry and further measures of ventilation from ambulatory recordings (as further indicators of training manipulation success)(Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions, patients perform self-assessments on a daily basis throughout, pre- and post-treatment 2h monitoring)
- FeNO(Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions)
- airway hyperreactivity by methacholine(at pretreatment and optionally at 1 month follow up)
- spirometric lung function and respiratory resistance (as further indicators of asthma pathophysiology)(Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions, patients perform self-assessments on a daily basis throughout.)
- reported symptoms(Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions, patients perform self-assessments on a daily basis throughout)
- monitored bronchodilator use(Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions, patients record usage throughout treatment)
- effects on perceived general control of asthma management, asthma self-efficacy, and impact and control of asthma triggers (as an indicator of asthma self-management)(Measured at pre-treatment, post-treatment, 1-month follow-up, and 6-month follow-up, at the beginning of each of the five weekly training sessions)
Investigators
Alicia Meuret
Associate Professor
Southern Methodist University